Health and medicine
Daily aspirin for healthy adults
Partly documented
Earlier use does not prove universal government endorsement; explicit NICE negative recommendation dates to 2023.
Fact-check
Use for primary prevention documented, but a blanket official recommendation for all healthy older adults is not; key NICE update is January 2023.
The evidence
Links go to the original records: Hansard, legislation, official guidance and news reports. A before-and-after pair is not always proof of a direct contradiction, so read the originals for exact wording.
After: what changed
Context
- MHRA: aspirin not licensed for primary prevention, 2009 (opens in new tab)
Government regulator — Original universal endorsement still missing
What the source documents claim
These are summaries from the original documents behind this archive. They have not been checked word for word. Where they differ from the fact-check above, the fact-check is the more reliable account.
Daily Low-Dose Aspirin for Primary Prevention (Pre-2019)
Document A, case 06
- Original advice
- For years, UK clinical practice and NHS health guidance widely supported daily low-dose aspirin for healthy older adults to prevent first-time heart attacks and strokes.
- How it was framed
- Primary care protocols relied on early cardiovascular trial meta- analyses and Department of Health vascular risk guidance indicating broad preventative benefits.
- Later change
- Updated National Institute for Health and Care Excellence (NICE) clinical guidelines reversed this recommendation for adults without existing cardiovascular disease, concluding that major gastrointestinal and brain bleeding risks outweighed any preventative benefit.
Register entry 06. Last reviewed: 12 November 2026.